首页|他克莫司联合泼尼松治疗多发性肌炎/皮肌炎合并间质性肺病的效果

他克莫司联合泼尼松治疗多发性肌炎/皮肌炎合并间质性肺病的效果

扫码查看
目的:探讨他克莫司联合泼尼松治疗多发性肌炎/皮肌炎合并间质性肺病的临床效果.方法:回顾分析2018年4月—2023年4月泉州医学高等专科学校附属人民医院78例多发性肌炎/皮肌炎合并间质性肺病患者,根据治疗方案不同分为对照组(环磷酰胺联合泼尼松治疗,43 例)和观察组(他克莫司联合泼尼松治疗,35 例),两组均治疗 24 周.比较两组治疗前、治疗12周、治疗24周时免疫学指标[免疫球蛋白(Ig)G、IgA、IgM、补体C3、补体C4]、炎症因子水平[白介素(IL)-6、IL-10、C反应蛋白(CRP)]、肺功能指标[用力肺活量占预计值百分比(FVC%pred)、肺一氧化碳弥散量占预计值百分比(D1CO%pred)],统计两组用药期间不良反应发生情况.结果:两组治疗前至治疗24周时IgG、IgA、IgM、IL-6、IL-10、CRP均逐渐降低,补体C3、补体C4、FVC%pred、D1CO%pred均逐渐升高(P<0.05),但组间比较,差异无统计学意义(P>0.05).治疗期间,观察组不良反应发生率低于对照组(P<0.05).结论:他克莫司联合泼尼松方案在改善多发性肌炎/皮肌炎合并间质性肺病患者免疫功能、减轻炎症反应、提高肺功能方面与环磷酰胺联合泼尼松方案效果相当,但他克莫司联合泼尼松方案的安全性更高.
Effect of Tacrolimus Combined with Prednisone in the Treatment of Polymyositis/Dermatomyositis Complicated with Interstitial Lung Disease
Objective:To explore the clinical efficacy of tacrolimus combined with prednisone in the treatment of polymyositis/dermatomyositis with interstitial lung disease.Method:A retrospective analysis was conducted on 78 patients with polymyositis/dermatomyositis complicated with interstitial lung disease in our People's Hospital Affiliated of Quanzhou Medical College from April 2018 to April 2023.According to different treatment plans,they were divided into a control group(43 patients treated with cyclophosphamide combined with prednisone)and an observation group(35 patients treated with tacrolimus combined with prednisone).The immunological indicators[immunoglobulin(Ig)G,IgA,IgM,complement C3,complement C4],levels of inflammatory factors[interleukin-6,IL-10,C-reactive protein(CRP)],lung function indicators[percentage of forced lung capacity to expected value(FVC%pred),and percentage of carbon monoxide diffusion in the lungs(D1CO%pred)]before treatment,at 12 weeks and 24 weeks of treatment were compared between two groups,and the occurrence of adverse reactions during the medication period were recorded between the two groups.Result:IgG,IgA,IgM,IL-6,IL-10 and CRP were gradually decreased,and complement C3,complement C4,FVC%pred and D1CO%pred were gradually increased in the two groups from before treatment to 24 weeks of treatment(P<0.05),while there was no statistical significant difference between groups or interactions(P>0.05).During the treatment,the incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:The combination of tacrolimus and prednisone is equivalent in improving immune function,reducing inflammatory response,and enhancing lung function in patients with polymyositis/dermatomyositis complicated with interstitial lung disease compared to the combination of cyclophosphamide and prednisone.However,the safety of the combination of tacrolimus and prednisone is higher.

PolymyositisDermatomyositisInterstitial lung diseasePrednisoneTacrolimus

董学峰、常乐、傅金木

展开 >

泉州医学高等专科学校内科教研室,福建 泉州 362000

泉州医学高等专科学校附属人民医院呼吸内科,福建 泉州 362000

多发性肌炎 皮肌炎 间质性肺病 泼尼松 他克莫司

泉州市科技计划

2022NS072

2024

中国药物滥用防治杂志
中国药物滥用防治协会 军事医学科学院毒物药物研究所

中国药物滥用防治杂志

影响因子:0.584
ISSN:1006-902X
年,卷(期):2024.30(3)
  • 15